Cetuximab (C225) (Synonyms: C225) |
| Katalog-Nr.GC34217 |
Cetuximab (C225) ist ein chimärer monoklonaler Antikörper, der durch die Fusion der variablen Region des murinen anti-EGFR monoklonalen Antikörpers M225 und der konstanten Region des menschlichen IgG1 erzeugt wurde.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 205923-56-4
Sample solution is provided at 25 µL, 10mM.
Cetuximab (C225) ist ein chimärer monoklonaler Antikörper, der durch die Fusion der variablen Region des murinen anti-EGFR monoklonalen Antikörpers M225 und der konstanten Region des menschlichen IgG1 erzeugt wurde. Der erzeugte Antikörper behält eine hohe Affinität und Spezifität für EGFR und reduziert die Immunogenität.[1] Cetuximab bindet mit hoher Affinität an FcγRI (EC50 = 0.13 nM) und FcγRIIIa (EC50 = 6 nM). Es induzierte effektiv ADCC über mehrere Tumorzelllinien hinweg.[4] Die Behandlung mit 100 μg/ml Cetuximab für 24 Stunden verstärkt die zytotoxische Wirkung der RSL3-Behandlung bei KRAS-mutierten CRC-Zellen.[2]
In vitro-Experimente zeigten, dass Bestrahlung die cetuximab (0,5 μg/ml)-vermittelte ADCC und die Aktivierung von NK-Zellen verstärkt.[3] Die Behandlung mit 20 μg/ml Cetuximab hemmte die Proliferation der parentalen UMSCC1-Zelllinie (UMSCC1-P), während die drei HNSCC Cetuximab-resistenten Klone (C2, C5 und C11) vollständig refraktär gegenüber Cetuximab waren.[6]
In vivo-Experimente zeigten, dass Cetuximab (13 mg/kg, s.c.) die hemmenden Wirkungen von RSL3 und RSL3-induzierter Ferroptose verstärkt.[2] In vivo, nach i.v.-Injektion von 4 Dosen von 10 mg/kg Körpergewicht, zeigte sich, dass Cetuximab das Tumorwachstum bei SCC1-Tumor-tragenden Mäusen deutlich hemmte.[5] In vivo-Experimente illustrierten, dass mit Cetuximab (50 mg/kg, i.p.) behandelte Tumore ein verzögertes Wachstum aufwiesen, wenn Mäuse mit der NSCLC-H226-Zelllinie individuell mit 2x10^6 Tumorzellen in die dorsale Flanke inokuliert wurden.[6]
References:
[1]. Xiong HQ, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004 Jul 1;22(13):2610-6.
[2]. Yang J, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021 Nov 13;12(11):1079.
[3]. Jin WJ, et al. Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. Front Immunol. 2020 Nov 12;11:591139.
[4]. Patel D, et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies. 2010;19(4):89-99.
[5]. Niu G, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):2095-105.
[6]. Iida M, et al. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 Sep;15(9):2175-86.
| Cell experiment [1]: | |
Cell lines | SCC1 and UM-SCC-22B cells |
Preparation Method | The toxicity of cetuximab to SCC1 and UM-SCC-22B cells was determined by MTT assay. At 72 h or 120 h after treatment with different doses of cetuximab (ranging from 0.1 nM to 0.5 μM), the culture medium was replaced and 50 μl of 1.0 mg/ml sterile filtered 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT; Sigma) was added to each well. |
Reaction Conditions | 0.1 nM to 0.5 μM at 72 h or 120 h |
Applications | Treatment with cetuximab produced only modest inhibition of cell proliferation on SCC1 cells in vitro as determined by MMT assay. |
| Animal experiment [2]: | |
Animal models | BALB/c (nu/nu) female nude mice |
Preparation Method | Xenografts were established in female nude mice (BALB c[nu/nu]) by subcutaneous injection of head and neck squamous cell carcinoma cell lines a UT-SCC-14 and b UT-SCC-2. Cetuximab (1 mg/injection) was administered by intraperitoneal injection at day 10, 13 and 16. The tumour size was recorded at an interval of 2–3 days, n = 10-14. |
Dosage form | 1 mg, i.p. |
Applications | Cetuximab treatment showed reduction in the nuclear accumulation of HIF-1α, while the overall HIF-1α expression was not significantly altered. And after cetuximab treatment a downregulation of CAIX was only found in UT-SCC-14 xenografts. Cetuximab treatment affects the tumour growth and the tumour partial oxygen pressure as measured by LiPc EPR oximetry. |
References: | |
| Cas No. | 205923-56-4 | SDF | |
| Überlieferungen | C225 | ||
| Canonical SMILES | [Cetuximab] | ||
| Formula | C6484H10042N1732O2023S36 | M.Wt | 145543.35 |
| Löslichkeit | Storage | Store at 4°C, do not freeze | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0069 mL | 0.0344 mL | 0.0687 mL |
| 5 mM | 0.0014 mL | 0.0069 mL | 0.0137 mL |
| 10 mM | 0.0007 mL | 0.0034 mL | 0.0069 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: ≥98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *